Teng Yvonne Hui-Fang, Tan Puay-Hoon, Chia Sing-Joo, Zam Nor Azhari Bin Mohd, Lau Weber Kam-On, Cheng Christopher Wai-Sam, Bay Boon-Huat, Yip George Wai-Cheong
Department of Anatomy, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
Mod Pathol. 2008 Jul;21(7):893-901. doi: 10.1038/modpathol.2008.70. Epub 2008 May 16.
Chondroitin sulfate is a structurally diverse glycosaminoglycan, which contains a variable degree of sulfation that helps to determine its biological function. It is involved in the regulation of cellular activity and has been implicated in carcinogenesis. To determine if the non-sulfated chondroitin backbone has a functional role in prostate cancer, we analyzed its expression by immunohistochemistry using the 1B5 monoclonal antibody and a set of tissue microarrays constructed with 227 prostate specimen cores from 81 cases of benign prostate tissue and 77 cases of prostate cancer, of which 69 of these cases are matched. Non-sulfated chondroitin was found in the secretory epithelial cells and stromal regions of both prostatic adenocarcinoma and benign prostatic tissues, as well as in the basal cells of benign glands. A higher percentage of cancerous cells were stained positively for non-sulfated chondroitin as compared with benign secretory cells of the same patient. Cancerous cells stained more intensely for non-sulfated chondroitin. This increase in percentage of cells stained and increase in staining intensity were associated with higher pathological T stage and extraprostatic extension. Non-sulfated chondroitin expression (either staining intensity or percentage of cells stained) in adenocarcinoma and its peritumoral stroma correlated significantly with several clinicopathological parameters of unfavorable outcome, including higher pathological T stage and Gleason score, presence of tumor in both prostatic lobes, extraprostatic extension, seminal vesicle involvement and preoperative prostate-specific antigen levels. These data suggest that non-sulfated chondroitin is a potentially useful biomarker for prostate cancer, and may be involved in regulating prostate cancer behavior.
硫酸软骨素是一种结构多样的糖胺聚糖，其硫酸化程度各异，这有助于决定其生物学功能。它参与细胞活性的调节，并与癌症发生有关。为了确定非硫酸化软骨素骨架在前列腺癌中是否具有功能作用，我们使用1B5单克隆抗体通过免疫组织化学分析了其表达情况，并使用了一组组织微阵列，这些微阵列由来自81例良性前列腺组织和77例前列腺癌的227个前列腺标本芯构建而成，其中69例病例是匹配的。在前列腺腺癌和良性前列腺组织的分泌上皮细胞和基质区域以及良性腺体的基底细胞中均发现了非硫酸化软骨素。与同一患者的良性分泌细胞相比，癌细胞中非硫酸化软骨素的阳性染色百分比更高。癌细胞中非硫酸化软骨素的染色更强烈。染色细胞百分比的增加和染色强度的增加与更高的病理T分期和前列腺外侵犯有关。腺癌及其瘤周基质中非硫酸化软骨素的表达（无论是染色强度还是染色细胞百分比）与几个不良预后的临床病理参数显著相关，包括更高的病理T分期和Gleason评分、双侧前列腺叶肿瘤的存在、前列腺外侵犯、精囊受累和术前前列腺特异性抗原水平。这些数据表明，非硫酸化软骨素是前列腺癌的一种潜在有用的生物标志物，并且可能参与调节前列腺癌的行为。
